CRNX vs NTRA
Crinetics Pharmaceuticals, Inc. vs Natera, Inc. — AI-powered side-by-side comparison
CRNX
Crinetics Pharmaceuticals, Inc.
69
Buy
VS
| Metric | CRNX | NTRA |
|---|
| AI Score |
69
|
67
|
| Price |
$84.69
|
$309.83
|
| P/E Ratio |
-16.77×
|
-227.89×
|
| ROE |
-46.9%
|
-12.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.2%
|
65.3%
|
| Debt / Equity |
0.04×
|
0.13×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
65.5
|
| Beta |
0.1302
|
1.514
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for CRNX versus NTRA.
CRNX leads by 2 points.
CRNX scores 69/100 (Buy) versus NTRA at 67/100 (Buy).
CRNX Committee View
80% agreement
5 analysts
The primary driver is 3 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 90 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 90 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
NTRA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 37.8% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Price-to-book of 18.5x prices in significant intangible value — Value
- ROE of only -11.7% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 34.9% signals elevated volatility — Risk